Cantargia

Cantargia (OMX: CANTA)

Currency in SEK

Last close As at 27/09/2023

SEK4.08

▲ −0.04 (−0.97%)

Market capitalisation

SEK682m

Overview
Price performance
Financials
Research
Thematics

Cantargia is a clinical-stage biotechnology company based in Sweden. It is developing two assets against IL1RAP, CAN04 and CAN10. CAN04 is being studied in several solid tumours with a main focus on non-small cell lung cancer (NSCLC) and pancreatic cancer. The most advanced trial is in Phase II.

Increasing understanding of inflammation in malignant processes now includes findings that cytokines are not only produced by the immune cells, but that cancer itself can produce certain cytokines and the associated receptors to escape from the immune response. Therefore, cytokines represent a potentially promising class of targets in oncology.

Latest Insights

Healthcare |
Flash note

19.04.23

Cantargia — Encouraging data for nadunolimab in CANFOUR

Healthcare |
Flash note

14.03.23

Cantargia — First patient treated in Phase II part of TRIFOUR

Healthcare |
Update

27.02.23

Cantargia — Next phase of clinical development in sight

Healthcare |
Update

11.11.22

Cantargia — Strong momentum in first nine months of FY22

Visit Website

Sector

Healthcare

Equity Analyst

Soo Romanoff

Managing Director - Head of Content, Healthcare

Key Management

Goran Forsberg

CEO

Balance Sheet

Forecast net cash (SEKm)

119.4

Forecast gearing ratio (%)

N/A

Share Price Performance

Price Performance
%	1M	3M	12M
Actual	1.3	(1.6)	11.9
Relative	2.7	3.2	(0.7)
52 week high/low	SEK9.0/SEK3.0

Financials

Cantargia is developing antibodies against IL1RAP. Data from its Phase IIa CANFOUR trial investigating nadunolimab in first-line NSCLC and pancreatic ductal adenocarcinoma (PDAC), support the hypothesis that nadunolimab has a synergistic benefit with chemotherapy and in Q223, patient enrolment was completed for this study. The company is now preparing for a Phase II/III trial in metastatic PDAC in collaboration with PanCAN and a follow-on randomised study in NSCLC. Additionally, the initial dose escalation phase was recently completed for the Phase II TRIFOUR study investigating nadunolimab for the treatment of triple-negative breast cancer. A second programme, CAN10, is being developed for the treatment of myocarditis and systemic sclerosis and the company intends to initiate Phase I trials in H223. Cantargia had a cash and short-term investment position of SEK287.1m at end-Q223.

Y/E Dec	EBITDA (SEKm)	PBT (SEKm)	EPS (öre)	P/E (x)	P/CF (x)
2021A	(366.8)	(366.5)	(365.80)	N/A	N/A
2022A	(377.9)	(371.8)	(290.43)	N/A	N/A
2023E	(302.1)	(306.6)	(183.58)	N/A	N/A
2024E	(286.9)	(292.6)	(175.20)	N/A	N/A

Initiation

Healthcare

07.06.18

Equities

Equities by Sector

Sectors

Investment Strategy

Latest

Equity strategy and market outlook – August 2023

Equity strategy and market outlook – July 2023

Equity strategy and market outlook – June 2023

Thematics

Latest

Shades of the 1970s

The long and winding road

MediaWatch – July 2023

About Edison

About Edison

Careers

Cantargia (OMX: CANTA)

Latest Insights

Cantargia — Encouraging data for nadunolimab in CANFOUR

Cantargia — First patient treated in Phase II part of TRIFOUR

Cantargia — Next phase of clinical development in sight

Cantargia — Strong momentum in first nine months of FY22

Sector

Equity Analyst

Key Management

Balance Sheet

Share Price Performance

Financials

Cantargia: Edison Open House Healthcare 2022

Cantargia — ‘Post-Novartis’ era has begun

Cantargia – executive interview

Cantargia — Sentiment affected, but fundamentals robust

Cantargia – executive interview

Cantargia — Novartis’s CANOPY-2 trial disappoints

Cantargia – Edison Open House interview

Cantargia — Buoyant on CANFOUR and CANOPY interims

Cantargia — Great equity story underpins large share issue

Executive interview – Cantargia

Cantargia — Excellent end to the year

Cantargia — CANFOUR study on track, US trial preparations

Cantargia — Full Phase I data presented at ASCO

Cantargia — Signs of growing interest in IL-1 pathway targets

Executive interview – Cantargia

Cantargia — Nidanilimab transitioning to Phase IIa

Cantargia — CANFOUR interim Phase I presented at ESMO

Cantargia — Phase IIa set to start in Q418

Cantargia — Tackling tumour promoting inflammation